NASDAQ$ARQT
Arcutis Biotherapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Arcutis reported financial results for the first quarter of 2022 and provided a business update.
Arcutis Biotherapeutics reported a net loss of $64.3 million for the quarter ended March 31, 2022. The company's cash, cash equivalents, and marketable securities totaled approximately $345 million. They are increasing commercial preparations for roflumilast cream and completed enrollment for roflumilast foam trials.
- Increased commercial preparations for roflumilast cream in advance of the PDUFA action date of July 29, 2022.
- Completed enrollment of Phase 3 trials of roflumilast foam in seborrheic dermatitis and scalp and body psoriasis.
- Enrolling pivotal Phase 3 trials of roflumilast cream in atopic dermatitis.
- Strong financial position with approximately $345 million in cash, cash equivalents, and marketable securities, providing cash runway into 2024.
Headline financials
Revenue & EPS history
Arcutis · Revenue · Quarterly
$0
Forward guidance
Arcutis anticipates three Phase 3 topical roflumilast clinical readouts and a potential launch in plaque psoriasis for the balance of 2022.
Tailwinds
- Potential treatment for plaque psoriasis and atopic dermatitis with Roflumilast cream.
- Alternative foam formulation of topical roflumilast for hair-bearing areas.
- Potential treatment for seborrheic dermatitis and scalp and body psoriasis with Roflumilast foam.
- Topical small molecule inhibitor of Janus kinase type 1 (JAK1) being developed for chronic hand eczema, vitiligo, and other inflammatory dermatoses.
- Reformulation efforts to develop an enhanced formulation of ARQ-252.
Headwinds
- Risks inherent in the clinical development process and regulatory approval process.
- The timing of regulatory filings.
- The timing and expenses of commercialization efforts.
- Ability to defend intellectual property.
- Statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+1.8%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-0.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+27.2%
Q3 2025
Best reaction
-15.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.2% | -9.3% | -9.4% | |
| Q4 2025 | +5.7% | -12.6% | -21.4% | |
| Q3 2025 | +27.2% | +28.9% | +57.6% | |
| Q1 2025 | -4.6% | +0.5% | +0.3% | |
| Q4 2024 | +8.4% | +5.2% | +28.9% | |
| Q3 2024 | +11.8% | +16.6% | +33.3% | |
| Q2 2024 | -14.6% | -13.1% | +7.1% | |
| Q1 2024 | +15.6% | +15.1% | +16.9% | |
| Q4 2023 | +7.4% | +21.5% | +2.3% | |
| Q3 2023 | +5.4% | -0.9% | -10.4% | |
| Q2 2023 | -2.0% | -6.5% | -21.0% | |
| Q1 2023 | -15.6% | -29.3% | -29.8% | |
| Q4 2022 | +4.4% | -2.7% | -31.8% | |
| Q3 2022 | +0.6% | +3.1% | -8.4% | |
| Q2 2022 | +13.2% | +11.8% | +8.6% | |
| Q1 2022 | -11.8% | -14.1% | -3.5% | |
| Q4 2021 | +1.1% | +12.6% | +10.7% | |
| Q3 2021 | -7.5% | -6.9% | -35.6% | |
| Q2 2021 | +3.1% | +5.2% | +4.1% | |
| Q1 2021 | -3.4% | -1.8% | -23.1% | |
| Q4 2020 | -0.1% | +3.6% | -10.5% | |
| Q3 2020 | -3.8% | +8.9% | +37.1% | |
| Q2 2020 | +1.7% | +1.8% | -6.5% | |
| Q1 2020 | +0.0% | -4.6% | -4.6% | |
| Q4 2019 | +0.0% | -4.6% | -4.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro